The development of a new medicinal product for human use is a lengthy process that usually takes from 10 to 15 years, with an average of 13 years from synthesis of a NCE to approval of a new drug application. Pharmaceutical R&D is cost-intensive and a single failure in advanced stages may compromise the entire process, meaning that all previous investment goes to waste. Despite the introduction of promising advancements during the last decade, such as ‘omics’ technologies, attrition rates during the drug development process are high and R&D expenditures have actually increased. As a result, the average cost of bringing a new drug to market, calculated around 1.8 billion dollars in 2010, keeps growing.

In view of this dire scenario, there is an urgent need for strategies that address such a low R&D productivity, which poses a challenge for both the pharmaceutical industry and patients’ healthcare. With many compounds showing insufficient efficacy in humans or causing serious adverse events in clinical phases, the main reason for these unacceptable attrition rates seems a lacking ability to identify and discontinue failed compounds already in early stages. Aiming to tackle this issue, Anaxomics offers an innovative approach to early product development and drug portfolio management based on the combination of cutting-edge systems biology with long-time expertise in the clinical, regulatory and drug development fields.

In a few words, our goal is to put companies in the track to success. Thanks to our TPMS technology, we advise decision makers on the safest and most effective compounds in their pipeline, while identifying those that have comparatively worse profiles. Anaxomics provides not only the mechanistic and predictive analysis of your products therapeutic performance, but we offer a full range of strategic knowledge to help you add value and differentiate your new developments. Hence, our services encompass the following aspects:

Current situation and market analysis – In-depth market analysis to identify potential competitors of your compounds in the therapeutic area of interest with the aim of evaluating their commercial potential. [+]

Efficacy analysis – A comprehensive efficacy assessment that compares the candidates in your pipeline in order to identify the ones with more potential for treating the indication of interest. We help you to take the correct decisions, so that you can discontinue the development of compounds with unpromising efficacy profile or adopt alternative strategies when needed. For failed assets in advanced stages, we suggest new indications that may increase their value or provide an exit strategy. [+]

Safety analysis – A comprehensive analysis of the safety profile of your compounds, focusing on their adverse events and their impact on their quality. We can help you discard those candidates with worse safety profile based on a solid, evidence-backed scientific rationale. Besides, we can provide clues to avoid safety issues through patient stratification or combination with other drugs. [+]

Safety analysis – A comprehensive analysis of the safety profile of your compounds, focusing on their adverse events and their impact on their quality. We can help you discard those candidates with worse safety profile based on a solid, evidence-backed scientific rationale. Besides, we can provide clues to avoid safety issues through patient stratification or combination with other drugs. [+]

Integrated product assessment – A complete evaluation of the candidates in your pipeline to guide you in the early stages of development, encompassing the services listed above. A unique experience that combines the best systems biology can offer with in-depth market analysis and strategic differentiation advice.